Article
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2014
Graham Christopher N, Hechmati Guy, Hjelmgren Jonas, de Liège Frédérique, Lanier Julie, Knox Hediyyih, Barber Beth
Abstract excerpt
OBJECTIVE: To investigate the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC). DESIGN: A semi-Markov model was constructe...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.